Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.
Medicago and its partner GlaxoSmithKline could be on track to have a Phase III readout for their COVID-19 vaccine candidate by summer, which the Canadian company hopes would also demonstrate the efficacy of its plant-based vaccine platform.
Its approach is unlike any other COVID-19 vaccine developer: its proprietary technology uses the Australian tobacco plant N benthamiana as...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
